In Vitro Efficacy Testing Services for Cancer Pain

We provide robust and sensitive in vitro screening and characterization platforms for accelerating the discovery and screening of potential therapies for cancer pain. Our services enable the detailed investigation of candidate molecules targeting key receptors, ion channels, signaling pathways, and epigenetic regulators implicated in cancer pain mechanisms. This includes opioid receptors, voltage-gated ion channels, inflammatory mediators, and pain-related neurotransmitter systems. We can evaluate changes in nociceptive signaling, neuroinflammation, receptor binding, and downstream cellular responses that are central to cancer pain pathophysiology.

Our comprehensive in vitro testing menu includes receptor binding assays, functional cell-based assays, electrophysiological recordings, biochemical enzyme assays, and molecular profiling. These methodologies enable the assessment of compound efficacy, selectivity, mechanism of action, and target engagement relevant to cancer pain biology. Together, they support preclinical drug development by providing reliable and reproducible data on potential analgesic candidates.

Arachidonic acid as substrate: Used to assess the activity of enzymes such as cyclooxygenase or lipoxygenase involved in inflammatory mediator production relevant to cancer pain.

Arrestin protease recruitment assay: Measures the recruitment of arrestin to receptors, providing insights into receptor desensitization and biased agonism, especially for opioid receptors.

Bioluminescence resonance energy transfer (BRET) assay: Enables real-time monitoring of protein-protein interactions, such as receptor activation or signaling complex formation in pain pathways.

Cell-electrode impedance assay: Evaluates cellular responses to compounds by measuring changes in electrical impedance, useful for detecting cell morphology or motility changes.

Chemiluminescent assay: Detects the presence or activity of specific proteins or enzymes using light emission, allowing sensitive quantification of pain-related biomarkers.

DNA methylation assay: Assesses epigenetic modifications that can influence gene expression linked to chronic pain states in cancer.

Displacement of [125I]-iometopane: Used to evaluate binding affinities for dopamine transporters, which may modulate pain perception.

Displacement of [3H]-DADLE: Measures binding to delta opioid receptors, critical for understanding opioid-mediated analgesia.

Displacement of [3H]-DAMGO: Assesses ligand binding to mu opioid receptors, key targets for analgesic drug action.

Displacement of [3H]-DPDPE: Evaluates selective binding at delta opioid receptors, informing on analgesic selectivity.

Displacement of [3H]-HS665: Used for kappa opioid receptor binding studies, contributing to the understanding of kappa-mediated pain modulation.

Displacement of [3H]-SNC-80: Measures the interaction with delta opioid receptors, aiding in the assessment of potential analgesics.

Displacement of [3H]-U-50488: Determines kappa opioid receptor binding, relevant for kappa agonist/antagonist profiling.

Displacement of [3H]-U-69593: Another assay for kappa opioid receptor binding specificity and affinity.

Displacement of [3H]-mazindol: Used for norepinephrine and dopamine transporter binding, which may influence pain signaling.

Displacement of [3H]-naloxone: Assesses the affinity of compounds for opioid receptors, important for screening opioid antagonists.

Displacement of [3H]-naltrexone: Evaluates opioid receptor binding, supporting antagonist or partial agonist drug development.

Displacement of [3H]-naltrindole: Specific for delta opioid receptor binding studies.

Displacement of [3H]-nisoxetine: Used for norepinephrine transporter binding, relevant to modulation of neuropathic pain.

Displacement of [3H]-paroxetine: Assesses serotonin transporter binding, which can impact pain modulation.

Dynamic mass redistribution assay: Monitors integrated cellular responses to ligands, providing label-free detection of receptor activation.

ELISA assay: Quantifies proteins, peptides, or cytokines involved in pain and inflammation using antibody-based detection.

Enzyme immunoassay (EIA): Similar to ELISA, allows sensitive measurement of pain-related substances in cell or tissue samples.

Fluorescent assay: Utilizes fluorescence to detect molecular interactions or biochemical activity in pain signaling pathways.

GTPase assay: Measures G-protein activation downstream of GPCRs, such as opioid receptors, indicating receptor functional activity.

Homogeneous Time Resolved Fluorescence (HTRF) assay: Provides high-throughput quantification of molecular interactions or second messenger production in pain-relevant pathways.

Luciferine/luciferase assay: Assesses gene expression or ATP levels as indicators of cellular responses to analgesic compounds.

Mass spectrometry: Offers precise quantification and identification of metabolites, neurotransmitters, or signaling molecules involved in pain mechanisms.

NB33 recruitment assay: Evaluates beta-arrestin pathway activation, contributing to understanding GPCR signaling bias.

Patch-clamp assay: Measures ionic currents through individual channels, crucial for assessing ion channel modulators in pain research.

Patch-clamp assay (-40 mV): Specific voltage protocol for investigating channel activity under defined conditions relevant to neuronal excitability.

Prostaglandin E2 assay: Quantifies PGE2 production, a mediator of inflammation and pain in cancer tissues.

RNA assay: Detects changes in gene expression of pain-relevant targets or inflammatory mediators.

Radioactivity assay: Utilizes radiolabeled compounds to measure ligand binding or enzyme activity with high sensitivity.

Saturation binding assay: Determines binding capacity and affinity of receptors for ligands, informing drug-receptor interaction studies.

Surface plasmon resonance assay: Real-time, label-free analysis of molecular interactions, useful for characterizing binding kinetics.

Thromboxane B2 assay: Measures TBX2, an inflammatory mediator that can contribute to pain in cancer.

Voltage-clamp assay (-80 mV): Assesses ion channel activity under controlled voltage conditions, essential for pain signal transduction studies.

Whole-cell patch-clamp assay: Evaluates the overall ionic currents in cells, pivotal for functional characterization of pain-related ion channels.

Whole-cell patch-clamp assay (-110 mV): Specialized voltage protocol for detailed ion channel analysis.

Whole-cell patch-clamp assay (-120 mV): Enables assessment of channel behavior at hyperpolarized potentials.

Whole-cell patch-clamp assay (-80 mV): Standard voltage step for characterizing resting channel properties.

Whole-cell voltage-clamp assay: Measures ionic currents across the entire cell membrane, important for neuronal pain models.

Whole-cell voltage-clamp assay (-60 mV): Allows investigation of channel activity at physiologically relevant voltages.

[35S]-GTPgammaS binding assay: Measures GPCR activation by assessing G-protein coupling, essential for opioid and other receptor pharmacology.

cAMP accumulation assay: Quantifies intracellular cAMP as a measure of GPCR activity, relevant for assessing analgesic mechanisms.

Our assays measure a range of key pharmacological and biological parameters, including potency, efficacy, receptor affinity, and functional activity. These parameters are critical for evaluating the therapeutic potential, selectivity, and safety profile of candidate analgesics. By quantifying these metrics, we provide essential data to support lead optimization and decision-making in early-stage drug development.

EC-50: The concentration of a compound that produces 50% of its maximal effect, representing potency in functional assays.

IC-50: The concentration required to inhibit a specific biological or biochemical function by 50%, important for quantifying antagonist or inhibitor activity.

Kd: The dissociation constant for ligand-receptor binding, reflecting the affinity between a drug and its target.

Ki: The inhibition constant, indicating the binding affinity of an inhibitor for its target in competition assays.

MEC: Minimum effective concentration, the lowest concentration at which a compound elicits a detectable effect, guiding dose selection.

MED: Minimum effective dose, the smallest dose that produces a desired therapeutic effect, informing in vitro to in vivo translation.

MIC: Minimum inhibitory concentration, the lowest concentration needed to inhibit a biological function, relevant for identifying effective inhibitors.

pEC-50: The negative logarithm of EC-50, used for easier comparison of drug potency across compounds.

pIC-50: The negative logarithm of IC-50, facilitating comparison of inhibitor efficacy.

pKi: The negative logarithm of Ki, providing a standardized measure of binding affinity.

Recommended In Vitro Efficacy Tests

Opioid Receptor Delta 1

Our Opioid Receptor Delta 1 (DOR1) testing service supports cancer pain drug development by evaluating compounds targeting DOR1, a key modulator of cancer-related pain. Comprehensive assays—including radioligand displacement ([3H]-DPDPE, [3H]-naltrindole, [3H]-DADLE, [3H]-SNC-80), luciferase/luciferin, BRET, chemiluminescence, cAMP, arrestin recruitment, and cell impedance—assess drug-receptor interactions. Key parameters measured are EC50, IC50, pKi, Ki, MEC, pEC50, and pIC50, ensuring robust candidate profiling.

Opioid Receptor Kappa 1

Opioid Receptor Kappa 1 (KOR1) plays a crucial role in mediating cancer pain and is a key target for novel analgesics. KOR1 testing is essential for identifying compounds with optimal efficacy and safety profiles. Using advanced assays—such as radioligand binding ([3H]-U-50488, [3H]-U-69593, [3H]-HS665), cAMP accumulation, BRET, [35S]-GTPγS binding, and others—critical pharmacological parameters (EC-50, IC-50, Ki, pKi, pEC-50, pIC-50) are determined to guide drug development.

Opioid Receptor Mu 1

Opioid Receptor Mu 1 (MOR-1) is crucial in mediating cancer pain relief. Testing MOR-1 activity is vital for developing safer, more effective analgesics. Our service utilizes advanced assays—including cAMP accumulation, BRET, surface plasmon resonance, radioligand displacement ([3H]-naltrexone, [3H]-DAMGO, [3H]-naloxone), GTPγS binding, and more—to assess ligand binding, signaling, and efficacy. Key parameters measured include EC-50, IC-50, Kd, Ki, and pKi, ensuring comprehensive drug characterization.

Prostaglandin-Endoperoxide Synthase 1

Prostaglandin-Endoperoxide Synthase 1 (COX-1) is involved in prostaglandin synthesis, contributing to cancer pain. Our testing service evaluates COX-1 inhibition, crucial for developing effective cancer pain therapeutics. Key methods include ELISA, fluorescent assay, enzyme immunoassay (EIA), and Prostaglandin E2 assays, using arachidonic acid as substrate. The primary parameter measured is IC-50, enabling precise assessment of drug efficacy in inhibiting COX-1 activity.

Prostaglandin-Endoperoxide Synthase 2

Prostaglandin-Endoperoxide Synthase 2 (COX-2) is crucial in mediating cancer pain via increased prostaglandin production. Accurate COX-2 testing informs drug development by assessing inhibitor efficacy and pain modulation. Our service employs ELISA, EIA, fluorescent, RNA, and DNA methylation assays, using arachidonic acid and measuring prostaglandin E2 or thromboxane B2. Key parameters, including IC-50 and MIC, quantify drug potency and effectiveness, accelerating cancer pain therapeutic advancements.

Sodium Voltage-Gated Channel Alpha Subunit 5

The Sodium Voltage-Gated Channel Alpha Subunit 5 (Nav1.5) plays a key role in cancer pain signaling, making it a strategic target for analgesic drug development. Our testing service assesses compound effects on Nav1.5 using whole-cell patch-clamp assays at various holding potentials (-80, -110, -120 mV), whole-cell voltage-clamp, and fluorescent assays. The primary readout is IC-50, enabling precise evaluation of drug potency and efficacy for cancer pain therapeutics.

Sodium Voltage-Gated Channel Alpha Subunit 9

Sodium Voltage-Gated Channel Alpha Subunit 9 (NaV1.9) is implicated in cancer pain by mediating neuronal excitability and pain signaling. Testing its activity is crucial for developing targeted analgesics. Our service utilizes advanced techniques—including whole-cell patch-clamp, voltage-clamp, and patch-clamp assays at -40 mV and -80 mV—to assess drug effects on NaV1.9. The primary parameter measured is IC50, enabling precise evaluation of compound potency for cancer pain therapeutics.

Solute Carrier Family 6 Member 2

The Solute Carrier Family 6 Member 2 (SLC6A2) transporter regulates norepinephrine reuptake, playing a key role in cancer pain signaling. Testing SLC6A2 is vital for developing targeted cancer pain therapeutics. Our service uses displacement assays ([125I]-iometopane, [3H]-nisoxetine, [3H]-mazindol), mass spectrometry, radioactivity, and fluorescent assays to assess drug interactions. Main parameters analyzed include IC50, Ki, and MED, providing critical data for drug efficacy and potency evaluation.

Solute Carrier Family 6 Member 4

The Solute Carrier Family 6 Member 4 (SLC6A4) transporter modulates serotonin uptake, influencing cancer pain signaling. Testing SLC6A4 is crucial for developing effective cancer pain therapeutics. Our service employs displacement assays using [125I]-iometopane, [3H]-mazindol, and [3H]-paroxetine, along with radioactivity and fluorescent assays, to evaluate drug interactions. Key parameters measured include IC₅₀ and Kᵢ values, providing critical insights for candidate drug efficacy and selectivity.